Almac Expands UK Commercial Capacity
News Oct 05, 2012
Almac has announced that it has expanded its MHRA/FDA approved UK commercial packaging facility with the acquisition of a Noack N 623 blister packaging line from Romaco.
The acquisition comes in response to growing client demand for enhanced flexibility related to larger blister sizes and innovative multi unit blister formats, coupled to a requirement for non permeability and enhanced environmental protection, particularly product humidity control.
This highly flexible, cGMP compliant technology can be configured to process both thermoform and coldform materials, with maximum blister sizes of 220mm x 155mm.
With its automatic feeding system, filling inspection and ejection station and shorter set-up times, the line provides increased productivity, processing over 25,000 blisters per hour, including multi-product blisters.
“Blister size and dosage formats are becoming increasingly more complex. Additionally, product handling for innovative new molecules often requires enhanced environmental controls. This investment allows Almac, through its Pharma Services business unit, to offer this additional flexibility,” says Geoff Sloan VP of Manufacturing Operations.
“Through this acquisition, coupled with our immanent entry into the US commercial packaging market, we continue to expand our capabilities and flexibility to meet our client’s needs.”
“The blister technology from Romaco Noack offers high OEE values and low lifecycle costs. Product changeovers are carried out easily and cleaning is quickly done. Our machines prove themselves flexible in operation and versatile in use.”, says Bernd Webel, Sales Director, Romaco.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018